Recent Journal Articles

2023

• Yu, T., Jin, S., Li, C., Chambers, J. D., & Hlávka, J. P. (2023). Factors Associated with Biosimilar Exclusions and Step Therapy Restrictions Among US Commercial Health Plans. BioDrugs, 1-10.

• Handels, R. L., Green, C., Gustavsson, A., Herring, W. L., Winblad, B., Wimo, A., Hlávka, J. P.  ... & IPECAD modeling workshop 2020 participants. (2023). Cost‐effectiveness models for Alzheimer's disease and related dementias: IPECAD modeling workshop cross‐comparison challenge. Alzheimer's & Dementia, 19(5), 1800-1820.

• Chhugani, K., Frolova, A., Salyha, Y., Fiscutean, A., Zlenko, O., Reinsone, S., ... Hlávka, J. P. & Mangul, S. (2022). Remote opportunities for scholars in Ukraine. Science, 378(6626), 1285-1286.

2022

• Hlávka, J. P., Tysinger, B., Jeffrey, C. Y., & Lakdawalla, D. N. (2022). Access to Disease-Modifying Alzheimer’s Therapies: Addressing Possible Challenges Using Innovative Payment Models. Value in Health, 25(11), 1828-1836.

• Walmsley, T., Rose, A., John, R., Wei, D., Hlávka, J. P., Machado, J., & Byrd, K. (2023). Macroeconomic consequences of the COVID-19 pandemic. Economic Modelling, 120, 106147.

• Hlávka, J. P., Yu, J. C., & Lakdawalla, D. N. (2022). Crosswalk between the Mini‐Mental State Examination and the Telephone Interview for Cognitive Status (TICS‐27/30/40). Alzheimer's & Dementia, 18(11), 2036-2041.

• Hlávka, J. P., Lavelle, T. A., Neumann, P. J., & Lin, P. J. (2022). Addressing Challenges to Alternative Payment Models for New Alzheimer’s Disease Therapies for US Commercial Payers. PharmacoEconomics, 1-6. Paper Full-Text

• Yu, J. C., Hlávka, J. P., Joe, E., Richmond, F. J., & Lakdawalla, D. N. (2022). Impact of non‐binding FDA guidances on primary endpoint selection in Alzheimer's disease trials. Alzheimer's & Dementia: Translational Research & Clinical Interventions, 8(1), e12280. Paper Full-Text

2021

• Hlávka, J. P., A. Kinoshita, S. Fang, A. Hunt. (2021). Clinical Outcome Measure Crosswalks in Alzheimer's Disease: A Systematic Review. Journal of Alzheimer's Disease. Paper URL.

• Hlávka, J. P., Jeffrey C. Yu, Dana P. Goldman & Darius N. Lakdawalla. (March 2021). The Economics of Alternative Payment Models for Pharmaceuticals, The European Journal of Health Economics. Full-text PDF. Paper URL

2020

• Shekelle, P.G., Goldman D.P., Hlávka J.P., ... (August 2020). Prospects for Future Advances in Alzheimer’s Disease. USC Schaeffer Center White Paper. Full-Text PDF. Paper URL.

• Mattke, S., Kyu Cho, S., Bittner, T., Hlávka, J. P., Hanson, M. (August 2020). Blood‐based biomarkers for Alzheimer's pathology and the diagnostic process for a disease‐modifying treatment: Projecting the impact on the cost and wait times. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring. Full-text PDF. Paper URL 

• Hlávka, J. P. (2020). Security, privacy, and information-sharing aspects of healthcare artificial intelligence. Artificial Intelligence in Healthcare. Academic Press (Elsevier), pp.235-270. Full-Text PDF. Book URL. Chapter link.

• Hlávka, J. P., Mattke, S., & Wilks, A. (2020). The Potential Benefits of Deferred Payment for a Hypothetical Gene Therapy for Congestive Heart Failure: A Cost-Consequence Analysis. Applied Health Economics and Health Policy, 1-9. Full-Text PDF. Paper URL.

• Mulligan, K., Lakdawalla, D., Neumann, P. J., Wilensky, G. R., Goldman, D. P., Katz, R. J., Hlávka, J.P. ... & Ryan, M. (2020). Health Technology Assessment For The US Healthcare System: A White Paper From the USC Schaeffer Center ‒ Aspen Institute Advisory Panel on Health Technology Assessment in the US. USC Schaeffer Center and Aspen Institute. Full-Text PDF. Paper URL.

2018-2019

• Hlávka, J. P., Lin, P. J., & Neumann, P. J. (2019). Outcome Measures for Oncology Alternative Payment Models: Practical Considerations and Recommendations. The American Journal of Managed Care, 25(12), e403-e409. Full-Text PDF. Paper URL.

• Lam, J., Hlávka, J. P., & Mattke, S. (2019). The potential emergence of disease-modifying treatments for Alzheimer disease: the role of primary care in managing the patient journey. The Journal of the American Board of Family Medicine, 32(6), 931-940. Full-Text PDF. Paper URL.

• Hlavka, J. P., Soeren Mattke, and Jodi L. Liu, Assessing the Preparedness of the Health Care System Infrastructure in Six European Countries for an Alzheimer's Treatment, Santa Monica, Calif.: RAND Corporation, RR-2503-BIOG, 2018.  Full-Text PDF. Paper URL.

Other Health Policy Research 

• Bibbins-Domingo, K., Helman, A., & National Academies of Sciences, Engineering, and Medicine. (2022). Key Trends in Demographic Diversity in Clinical Trials. In Improving Representation in Clinical Trials and Research: Building Research Equity for Women and Underrepresented Groups. National Academies Press (US).

• The economics of alternative payment models for pharmaceuticals (2021), with Jeffrey C. Yu, Dana P. Goldman & Darius N. Lakdawalla. The European Journal of Health Economics. PDF

• Three Essays in Health Economics (dissertation), Pardee RAND Graduate School (2018)

• Assessing the Preparedness of the Health Care System Infrastructure in Six European Countries for an Alzheimer's Treatment, RAND Corporation, with Jodi Liu and Soeren Mattke (2018)

• Assessing the Preparedness of the U.S. Health Care System Infrastructure for an Alzheimer's Treatment, RAND Corporation, with Jodi L. Liu, Richard Hillestad, and Soeren Mattke (2017)

• Biosimilar Cost Savings in the United States, RAND Corporation, with Andrew W. Mulcahy and Spencer R. Case (2017)

• Challenges to the Sustainability of the U.S. Public Cord Blood System, RAND Corporation, with Kandice A. Kapinos, Brian Briscombe, Tadeja Gracner, Aaron Strong, Christopher Whaley, Emily Hoch, Jakub P. Hlavka, Spencer R. Case, Peggy G. Chen (2017)

Technology and Security Policy 

• Lessons from Others for Future U.S. Army Operations in and Through the Information Environment, RAND Corporation, with Christopher Paul, Colin P. Clarke, Michael Schwille, Michael A. Brown, Steven S. Davenport, Isaac R. Porche III, and Joel Harding (2018)

• U.S. Presence and the Incidence of Conflict, RAND Corporation, with Angela O'Mahony, Miranda Priebe, Bryan Frederick, Jennifer Kavanagh, Matthew Lane, Trevor Johnston, Thomas S. Szayna, Stephen Watts, and Matthew Povlock (2018)

• Security Sector Reform in Ukraine, RAND Corporation, with Olga Oliker, Lynn E. Davis, Keith Crane, Andrew Radin, Celeste Gventer, Susanne Sondergaard, James T. Quinlivan, Stephan B. Seabrook, Jacopo Bellasio, Bryan Frederick, and Andriy Bega (2016)

• Expanding Flight Research: Capabilities, Needs, and Management Options for NASA's Aeronautics Research Mission Directorate, RAND Corporation, with Jan Osburg, Philip S. Anton, Frank Camm, Jeremy M. Eckhause, Jaime L. Hastings, James G. Kallimani, Thomas Light, Chad J. R. Ohlandt, Douglas Shontz, Abbie Tingstad, and Jia Xu (2016)

Book Reviews

• Immunotherapy's Promise, Health Affairs, Volume 38, No. 6 (June 2019)

• Cleaning Up Medical Research, Health Affairs, Volume 36, Issue 11 (November 2017)

• Portfolio Society: On the Capitalist Mode of Prediction, Science and Public Policy, Volume 44, Issue 6 (December 2017)

Select Presentations

• July 2020 “Impact of blood biomarkers on cost and wait time in diagnosing treatment-eligible patients for Alzheimer’s disease: A simulation study”, Alzheimer's Association International Conference 2020, Los Angeles (with Soeren Mattke)

• June 2019 “Assessing the Preparedness of the Health Care System Infrastructure in Six European Countries for an Alzheimer's Treatment”, AcademyHealth 2019, Washington DC

• June 2019 “The Benefits of Deferred Payment in Congestive Heart Failure Gene Therapy”, AcademyHealth 2019, Washington DC (poster, presentation)

• May 2019 “The Benefits of Deferred Payment in Congestive Heart Failure Gene Therapy”, ISPOR 2019, New Orleans (poster)

• June 2019 “Assessing the Preparedness of the Health Care System Infrastructure in Six European Countries for an Alzheimer's Treatment”, ASHEcon 2019, Washington DC

• July 2019 “Estimated Impact of Diagnostic Tools for Primary Care Settings on Demand for Specialist Visits for Patients with Prodromal Alzheimer’s Disease”, Alzheimer's Association International Conference 2019, Los Angeles (with Soeren Mattke)

• Sept. 2019 “Alzheimer’s Disease Modeling with the Future Elderly Model”, International Pharmaco-Economic Collaboration on Alzheimer's Disease Modeling Workshop (IPECAD), Stockholm, Sweden 

• Sept. 2019 Roundtable on the Financing of High-Cost Therapies, Health Affairs Committee of the Parliament of the Czech Republic, Prague, Czech Republic

• November 2018 “Future Biosimilar Spending”, APPAM Fall Research Conference 2018 (From Evidence to Policy on Prescription Drug Spending) (with Andrew Mulcahy)

• October 2018 Assessing the Preparedness of the Health Care System Infrastructure in Six European Countries for an Alzheimer's Treatment, Alzheimer Europe 2018, Barcelona (with Jodi Liu)

• July 2018 “How Prepared is the US Health Care System for a Future Alzheimer’s Treatment?”, HHS ASPE: Advisory Council on Alzheimer's Research, Care, and Services (with Jodi Liu and Soeren Mattke)

• June 2018 “Assessing the Preparedness of the U.S. Health Care System Infrastructure for an Alzheimer’s Treatment”. AcademyHealth Research Meeting 2018, Seattle, Washington (with Jodi Liu)

• June 2017 “Three-part payment model for PCSK9 inhibitors”, Cardiovascular Clinical Trialists Forum 2017, Washington D.C. 

• October 2017 “Trends in biosimilar spending”. AMCP Nexus 2017, Dallas, Texas (with Andrew Mulcahy)

• August 2017 “Review of frameworks in the analysis of genomic testing”, Australian Genomics National Conference, Brisbane, Australia (with Sarah Nowak)

• October 2015 Assessing Interoperability in NATO’s VJTF: 360° VJTF Interoperability Assessment Model. Inter-University Seminar on Armed Forces and Society 2015, Chicago, IL (with Lisa Jonsson)

My publications can be found at Google Scholar as well as the RAND Corporation's website and my USC homepage. 

IN REVIEW

1.    A Crosswalk between MMSE and TICS-27/30/40 in Adults over 65.

2. Modeling Early Disease-Modifying Therapies in Alzheimer’s Disease and Optimal Payment Models. 

3.    Estimating the Budget Impact of Regenerative Therapies in Current Late-Stage Clinical Trials. 

4.    An Analysis of Select Non-Drug Interventions in the COVID-19 Pandemic

DRAFTING

1.    The Effect of FDA Guidance on Endpoint Choice in Alzheimer’s Disease Trials. 

2.    The Effects of Traveler Contact Tracing on COVID-19 Incidence and Health Care Delivery. 

3.    International Validation of Alzheimer’s Disease Models. 

4.    Estimating Eligible Treatment Populations for Future AD Therapies Using the Health and Retirement Survey.